TECX Overview

Tectonic Therapeutic, Inc. is a biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Company’s lead asset, TX000045 (TX45), is a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). TX002100 (TX2100) is its second development candidate for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT).

Wall Street analysts forecast TECX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TECX is81.00 USD with a low forecast of 60.00 USD and a high forecast of 101.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Tectonic Therapeutic Inc revenue for the last quarter amounts to -21.52M USD, increased 53.78

Tectonic Therapeutic Inc. EPS for the last quarter amounts to -14461000.00 USD, decreased -14.05

Tectonic Therapeutic Inc (TECX) has 60 emplpoyees as of March 12 2026.

Today TECX has the market capitalization of 653.24M USD.